Rafael Pharmaceuticals CPI-613 folfirinox

Rafael launches Phase III trial of pancreatic cancer drug

Rafael Pharmaceuticals has commenced the Phase III AVENGER 500 trial to examine CPI-613 (devimistat) in combination with modified folfirinox (mFFX)…